Subcutaneous Ketamine vs Troches: Patient Outcomes Compared

If you are comparing subcutaneous ketamine with troches, you are likely weighing two questions at once: which route produces better patient outcomes, and which one fits your actual life. They are not the same question, and neither has a single universal answer.

Subcutaneous (SC) ketamine involves injecting a small volume of liquid just beneath the skin — typically in the abdomen or thigh. Ketamine troches are compounded lozenges that dissolve against the cheek or under the tongue. Both deliver the same active molecule, but the route shapes how quickly the drug reaches the bloodstream, how much of the dose the body absorbs, what the session experience feels like, and where treatment can realistically happen.

This guide walks through those differences so you can bring specific, informed questions to a prescribing clinician rather than sorting through abstracts on your own.

How Subcutaneous Ketamine Is Administered

Subcutaneous ketamine is given by injecting a small amount of solution just beneath the skin. Because it bypasses the digestive tract and first-pass liver metabolism, the body absorbs it efficiently. Pharmacological studies describe SC bioavailability in the range of approximately 90% or higher — substantially closer to intravenous delivery than to sublingual or oral routes.

Onset of noticeable effects typically occurs within 5–20 minutes. Sessions may be structured as a single injection or a slow infusion delivered subcutaneously over 30–60 minutes, depending on the clinical protocol. Effects during the active window include dissociation, altered perception, and sedation, similar to IV ketamine but with a somewhat slower pace of onset.

In the United States, SC ketamine for mood disorders is not an FDA-approved indication and is used off-label when prescribed by a clinician. It has a more established research and clinical use base in Australia and the United Kingdom, where clinicians have used SC protocols for treatment-resistant depression outside of hospital-based IV infusion settings.

How Ketamine Troches Work

Ketamine troches are compounded lozenges held against the mucous membrane of the cheek (buccal placement) or under the tongue (sublingual) for 15–30 minutes. A portion of the dose absorbs directly through the oral mucosa into the bloodstream, while the rest is swallowed and processed through the digestive system. Overall bioavailability is estimated at roughly 20–30%, which is why prescribed troche doses are typically expressed in much higher milligram amounts than IV or SC doses intended to produce a comparable absorbed effect.

Effects generally begin appearing 20–40 minutes after the troche starts dissolving, reach a peak somewhat later, and last approximately 60–90 minutes. Because troches are designed for home use under a clinician's structured protocol, patients dissolve them in a familiar setting without needles or clinic-based nursing supervision. For a session-by-session look at timing, the troche onset, peak, and duration timeline guide covers what to expect in detail. The compounding process behind each lozenge is explained in how troches are made.

Bioavailability and What It Means for Patient Outcomes

The gap in bioavailability between SC and sublingual routes matters most when you are reading outcome research. Studies that tested SC ketamine used doses calibrated for approximately 90% absorption. If a clinician is drawing on that research to inform a troche protocol, they need to account for the fact that a 100 mg troche delivers far less active drug to the bloodstream than a 100 mg SC injection of the same compound.

This is not a shortcoming unique to troches — it is a pharmacokinetic property that responsible prescribing protocols account for from the start. The practical implication is that comparing milligram doses directly across routes is not meaningful unless you know the intended absorbed amount for each. Published outcome studies for each route used route-specific dosing, so looking at SC outcomes alongside troche outcomes requires reading each body of research on its own terms rather than mapping numbers across.

For treatment-resistant depression, researchers have published antidepressant response data for SC ketamine — particularly in Australian and UK clinical settings — and separately for sublingual ketamine troches. The evidence base for IV ketamine is larger and longer-standing than for either. What any body of research means for a specific patient is a question for a clinician who knows their history, not something a comparison article can resolve.

Setting, Access, and Practical Logistics

Access is one of the most concrete differences for most patients in the United States. IV ketamine clinics have an established presence in many metropolitan areas, and some offer SC ketamine as well. But the number of US clinicians with structured SC ketamine protocols specifically for mood disorders is smaller, and SC is rarely listed as a primary service by telehealth psychiatric platforms.

Ketamine troches have become more available through telehealth-connected prescribing in states where that practice is permitted. A prescribing clinician writes an order, a licensed compounding pharmacy fills it, and the patient follows a structured home protocol with scheduled check-in visits. This does not mean troches are appropriate for everyone — patients with certain psychiatric histories, substance use concerns, or cardiovascular risk factors may need a more directly monitored route regardless of preference or logistics.

Patients who have already looked into intramuscular ketamine may find the troche vs IM ketamine comparison useful alongside this one. IM and SC routes share some similarities — both are injection-based, both have high bioavailability relative to sublingual administration, and both typically require clinical supervision at the injection site in standard US protocols.

SC Ketamine in Palliative and Pain Contexts

SC ketamine has a distinct and well-documented role in palliative and end-of-life care that is separate from its use in mood disorders. In these settings, SC infusions are valued for managing refractory pain and sometimes agitation in patients for whom IV access is difficult or burdensome to maintain. If you or someone you support is researching ketamine in the context of serious illness, the guide on ketamine in end-of-life care addresses that application separately.

The outcome data and patient experience for SC ketamine in pain and palliative contexts do not straightforwardly predict what a patient with treatment-resistant depression or anxiety should expect from SC ketamine in a psychiatric protocol. These are distinct clinical applications, even though the same route and compound are involved. Distinguishing them helps you evaluate studies and clinician recommendations more clearly.

Using This Comparison in a Clinical Conversation

The goal of this comparison is not to steer you toward one route — it is to give you vocabulary for a more productive clinical conversation. Rather than arriving with a decision already made, consider bringing the questions above and letting the clinician explain how each option fits your medical history, symptoms, and life situation.

Clinicians experienced in ketamine treatment often explain their route preferences in terms of the patients they see and the infrastructure they work within. Some clinicians favor SC for patients who benefit from more predictable absorption and can reliably access a clinic. Others work primarily with troches because their patients are geographically dispersed, prefer to avoid needles, or are stepping down from infusion-based care. Neither approach is inherently superior — both reflect a clinician's experience applied to a patient population.

Whichever route you discuss, ask how outcomes will be tracked. Strong protocols include structured symptom check-ins using validated rating tools at consistent intervals, not only an open-ended check-in. If a prospective clinician does not have a systematic approach to monitoring your response across sessions, that is a reasonable thing to ask about before starting any treatment. For broader context on what IV research means for patients using other delivery formats, the guide on what troche users should know about IV ketamine research provides useful background.